Company Overview
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +17.2%.
- 5-Year Trend Long-term compounding — revenue CAGR -13.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -13.22% |
| 1 Year: | 17.20% |
Stock Price Performance
| 1 Year: | +9.79% |
| 6 Months: | +2.61% |
| 3 Months: | +34.19% |
| 1 Month: | +0.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross9d ago
- RSI (14)55.32 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -13.2% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GERN Geron Corporation R2KR3KPHARMA | 1.57 | -14.27 | $1.01B | 0.00% | -14.94% | -28.28% | -13.22% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 537.00K | 174.00K | 163.00K | 191.00K | 318.00K | 208.00K | 165.00K | 375.00K | 57.00K | 101.00K | 131.00K | 171.00K | 52.00K | 43.00K | 108.00K | 137.00K | 107.00K | 109.00K | 123.00K | 73.00K | 297.00K | 21.00K | 29.00K | 164.00K | 304.00K | 882.00K | 28.27M | 39.60M | 49.04M | 47.23M | 51.84M | 57.48M |
| Operating Income | -9.46M | -9.48M | 27.02M | - | -9.08M | -8.91M | -3.88M | - | -7.49M | -6.73M | -7.24M | - | -7.44M | -7.24M | -6.80M | - | -11.30M | -15.22M | -15.97M | - | -16.87M | -16.76M | -20.02M | -28.45M | -28.89M | -25.67M | -28.68M | -27.98M | -39.95M | -40.09M | -51.95M | -47.61M | -56.13M | -69.33M | -28.21M | -16.70M | -12.45M | -13.89M | 158.00K | -12.50M |
| Net Income | -9.31M | -9.36M | 27.18M | -8.47M | -8.84M | -8.64M | -3.58M | -8.48M | -7.18M | -6.41M | -6.90M | -7.43M | -7.19M | -6.93M | -5.60M | -7.30M | -10.06M | -14.24M | -15.18M | -29.07M | -16.36M | -15.82M | -19.65M | -27.82M | -29.57M | -26.70M | -30.10M | -28.12M | -41.05M | -38.12M | -49.23M | -44.80M | -55.39M | -67.38M | -26.45M | -19.84M | -16.38M | -18.43M | -3.64M | -16.68M |
| Diluted EPS | - | - | 0.17 | - | - | - | -0.02 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.09 | -0.08 | -0.09 | -0.07 | -0.10 | -0.07 | -0.09 | -0.08 | -0.09 | -0.10 | -0.04 | -0.03 | -0.02 | -0.03 | -0.01 | -0.02 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.73M | 3.56M | 2.44M | 2.71M | 1.28M | 1.15M | 36.37M | 6.16M | 1.06M | 1.07M | 460.00K | 253.00K | 1.39M | 596.00K | 237.00K | - | - |
| Operating Income | -70.23M | -111.17M | -96.12M | -71.76M | -38.96M | -36.31M | -559.00K | -30.65M | -29.25M | -31.07M | -72.50M | -76.91M | -114.00M | -138.55M | -193.94M | -173.73M | -68.58M |
| Net Income | -70.18M | -111.38M | -96.85M | -68.88M | -38.38M | -35.67M | 46.00K | -29.54M | -27.92M | -27.02M | -68.55M | -75.62M | -116.11M | -141.90M | -184.13M | -174.57M | -83.50M |
| Diluted EPS | - | - | - | - | -0.30 | -0.23 | 0.00 | -0.19 | -0.18 | - | - | -0.28 | -0.35 | -0.37 | -0.32 | -0.27 | -0.13 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 233.58M | 160.05M | 99.80M | 67.34M | 172.51M | 148.76M | 130.25M | 110.31M | 185.28M | 165.52M | 270.73M | 226.03M | 190.57M | 394.08M | 593.78M | 570.54M |
| Total Equity | 168.46M | 172.58M | 192.74M | 146.60M | 85.65M | 59.76M | 130.71M | 142.13M | 122.38M | 103.80M | 177.73M | 135.16M | 210.95M | 126.42M | 80.00M | 247.95M | 280.32M | 225.87M |
| Cash & Equivalents | 109.35M | 34.60M | 45.97M | 16.11M | 22.06M | 12.99M | 42.80M | 21.25M | 12.81M | 16.34M | 10.57M | 13.64M | 9.93M | 34.87M | 56.84M | 70.02M | 79.02M | 77.56M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | 24.04M | 49.83M | 30.21M | 35.05M | 118.48M | 119.55M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | 30.36M | 59.78M | 99.62M | 110.58M | 146.13M | 313.46M | 344.67M |
| Current Liabilities | - | - | 40.85M | 13.44M | 14.15M | 7.59M | 41.80M | 6.63M | 7.87M | 6.52M | 7.55M | 28.16M | 30.94M | 45.52M | 76.69M | 108.07M | 88.30M | 111.54M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -43.37M | -44.29M | -62.39M | - | - | - | -24.20M | -18.37M | -20.56M | -21.01M | -43.83M | -66.65M | - | -127.38M | -167.74M | -218.62M | -111.04M |
| Investing Cash Flow | -83.00M | -48.45M | 32.14M | - | - | - | 73.00K | 8.76M | 22.97M | -77.72M | 27.40M | -105.32M | - | 62.07M | -180.32M | -106.00M | 107.25M |
| Financing Cash Flow | 51.63M | 104.11M | 386.00K | - | - | - | 2.58M | 1.17M | 1.11M | 92.97M | 19.50M | 168.35M | - | 87.26M | 362.02M | 334.37M | 2.27M |
| Capital Expenditure | -1.44M | -836.00K | -612.00K | -862.00K | -3.00K | -131.00K | -90.00K | -57.00K | - | -16.00K | -413.00K | -401.00K | - | -431.00K | -830.00K | -680.00K | -49.00K |
| Free Cash Flow | -44.81M | -45.13M | -63.00M | - | - | - | -24.29M | -18.43M | - | -21.02M | -44.24M | -67.05M | - | -127.81M | -168.57M | -219.30M | -111.09M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.95M | 13.96M | 9.75M | -1.52M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -4,069.2% | -3,120.0% | -3,942.4% | -2,648.9% | -3,036.5% | -3,149.3% | -1.5% | -497.3% | -2,746.9% | -2,914.9% | -15,762.0% | -30,400.4% | -8,183.7% | -23,246.6% | -81,832.9% | - | - |
| Net Margin % | -4,066.3% | -3,125.9% | -3,972.6% | -2,542.7% | -2,991.3% | -3,093.7% | 0.1% | -479.3% | -2,621.2% | -2,534.4% | -14,901.7% | -29,888.1% | -8,335.4% | -23,808.9% | -77,690.7% | - | - |
| ROE % | -40.7% | -57.8% | -66.1% | -80.4% | -64.2% | -27.3% | 0.0% | -24.1% | -26.9% | -15.2% | -50.7% | -35.8% | -91.8% | -177.4% | -74.3% | -62.3% | -37.0% |
| ROCE % | - | -57.7% | -65.6% | -83.8% | -65.2% | -27.8% | -0.4% | -25.0% | -28.2% | -17.5% | -52.8% | -32.1% | -63.2% | -121.7% | -67.8% | -34.4% | -14.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.64% | 49.12M | $74.16M |
| 2 | Soleus Capital Management, L.P. | 6.66% | 42.81M | $64.64M |
| 3 | RA Capital Management, L.P. | 6.66% | 42.81M | $64.64M |
| 4 | State Street Corporation | 5.58% | 35.86M | $54.14M |
| 5 | Citadel Advisors Llc | 4.52% | 29.04M | $43.85M |
| 6 | Vanguard Capital Management LLC | 4.24% | 27.25M | $41.15M |
| 7 | ClearBridge Investments, LLC | 3.06% | 19.65M | $29.67M |
| 8 | Eversept Partners, LP | 2.91% | 18.72M | $28.26M |
| 9 | Goldman Sachs Group Inc | 2.59% | 16.63M | $25.12M |
| 10 | Geode Capital Management, LLC | 2.27% | 14.56M | $21.98M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GERN
Geron Stock Price Forecast. Should You Buy GERN? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE9Zbm1pZC1ZUmxSMVdtbFNwaGJ0R2dzVVM5Y3NFZ2FTXzZFNjE2U19renJVN05WVTNPZm1fVkplc09yV2hPYmRUNw?oc=5" target="_blank">Geron Stock Price Forecast. Should You Buy GERN?</a> <font…
Geron (GERN) Stock Looks Reasonable On Sales But Weak On Returns - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQUmxVcnJaZE85RVoxOHJ6elVyNkoxVlJaRkdFMXpXVFJLaFM0cFIxNi1DTXFOZUNsQkh2bTVqZzM4c2NCNmRXb3pUTVVqTlBhRlA0QkZZS1ZPZnpERnZfNHlSVTFwRVAyNDNzWnBCLWU5N1FMaDQ2eXV4RnpMb25UYjlVTXJCeldFUGFpTz…
GERN Stock Rises As RYTELO Revenue Beats Expectations - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1EY1R2SEh3ZngtVmhiYzFNdHBLZ2NETjJXMEhMTFdLWUZtbFA2YlJLcWFyZ1NsdWpXWTB3U0g1SEp3bm5HclJwcTlYckhpeXhYTFRkVHhTQ1NBZzRzUXp6VTBMbE51NGxKRFktTEJyWWsyMnBJZFdSQlBn?oc=5" target="_blank">GER…
GERN Stock Rises As RYTELO Revenue Beat Fuels Guidance - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5zTDc3UE03TGQ1UC0yc2s5ZEF3SFRzSGxIZnlNOXdXNkI4SlRVUlVKcVZ0dFdxV1RGV3ZqcU1WWWdpYjZiVnIwY0J3VVp6QjZRcE1yYm93MzU3a2x5YTJ3c1RNNHl3ZU9TVGZhV1QwdXFiZmhOOVZOOA?oc=5" target="_blank">GERN …
$GERN stock is down 9% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOZEg4eWpYUFBiMTBqRU95bFlkclplX3FSV3hfMm1PVHN1RDgySEdFN2hCVjFlT3VlTV9QOWR4TG9kbWJhLUoxelRrUHJnUGJVQkF0ZW9xc1BuY05ZRHZiNmh5OVJaR29DWW00WEFUbHdXUkt0aGVIMlZqNGdBZXJ4aHFQcU44dnI2clNKei…
Geron Corporation (GERN) Stock Analysis: Unveiling a 134% Potential Upside in the Biotech Sphere - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxONUZUM3FOREJBNGtmbnk3VEJKV084a216anljbUdLUmFLNWtpd1UxYW5tLVBQWGZjdVlPWWtfM3J3bV9pRmdSSTU0OWlsazkzNU1GcWlvMndkQVo3SEJYTnZsSmVQOG1EMnBURlhWTy1uREE2QjhZd0VHWnFjdm55X1hfeG1GQVRKNXhzeW…
GERN — Frequently Asked Questions
What is the current share price of Geron Corporation (GERN)?
As of 2026-09-07 16:24 PDT, Geron Corporation (GERN) trades at $1.57 on NasdaqGS. Its 52-week range is $1.07 to $1.95.
What is the market capitalisation of GERN?
Geron Corporation (GERN) has a market capitalisation of $1.01B on NasdaqGS.
What is the P/E ratio of GERN?
GERN trades at a trailing price-to-earnings (P/E) ratio of -14.27. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.15.
What is the return on equity (ROE) of GERN?
GERN has a return on equity (ROE) of -28.28%. Its return on capital employed (ROCE) is -14.94%.
Is GERN a good stock to buy?
This page provides a data-driven analysis of Geron Corporation (GERN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.